Cure8 research brief
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to balance treatment benefit and safety.
Patients treated with infliximab (IV or SC), clinicians who manage biologic dosing and TDM, and researchers studying PK/PD and safety of biologics in IBD.
This abstract reports a prospective TDM-based cohort of IBD patients treated with IV or SC infliximab that assessed whether pharmacokinetic measures predict infection risk.
The authors measured preinfusion troughs (Ctrough), calculated cumulative exposure over 8 weeks (AUC0-8wk) from a validated population PK model, and linked repeatedly measured PK and clinical variables to infections using mixed-effects models.
They found that higher cumulative IFX exposure (AUC0-8wk), but not Ctrough, was associated with increased odds of infection. Corticosteroid use was associated with higher infection risk, while concomitant low-dose immunomodulators were associated with lower risk. The paper concludes AUC monitoring could better predict infection risk than trough monitoring.
This summary is based on the journal abstract provided on PubMed (structured content depth: abstract). It does not replace the full paper; readers should consult the full article for methods, definitions of infections, dosing details, and subgroup analyses before applying findings to care.
The source is an abstract from the Journal of Clinical Gastroenterology on PubMed. The finding is based on a prospective cohort and modeled PK exposure; full-text review is needed to evaluate definitions of infection, adjustment for confounders, and generalizability.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
